Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is expected to see strong growth in the coming years, driven by a focused management team, a solid cash position, and an increasing emphasis on recurring revenue. Despite integration challenges in the first quarter, the company's long-term growth strategy and commitment to cost reductions are expected to result in improved profitability. Their Enabling Tech segment and ExcelsiusGPS platform are important factors contributing to their strong performance and outlook. Additionally, with mostly independent board members and a focus on utilization and positive outcomes, GMED has the potential for continued success.

Bears say

Globus Medical is facing several challenges in their business, with slowing revenue growth, potential safety concerns given the stringent requirements for medical devices, and risks associated with their recent mergers and acquisitions. These factors may lead to stagnant margins and potential competition from larger medical device companies, which could disrupt their market share and lead to staffing and pricing pressures. There is also a risk that their strategic diversification may not yield positive results, leading to weaker financial performance.

Globus Medical (GMED) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 13 analysts, Globus Medical (GMED) has a Buy consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.